We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Alternating Nevirapine and Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Infected Persons Does Not Prolong Nevirapine Activity.
- Authors
de Jong, Menno D.; Loewenthal, Mark; Boucher, Charles A. B.; van der Ende, Ineke; Hall, David; Schipper, Pauline; Imrie, Allison; Weigel, Hugo M.; Kauffmann, Robert H.; Koster, Roel; Seville, Peter; Rocklin, Ross; Cooper, David A.; Lang, Joep M. A.
- Abstract
The potential use of an alternating treatment strategy with nevirapine and zidovudine in prolonging the antiretroviral effects of nevirapine was evaluated. Ten human immunodeficiency virus type 1 (HIV-1)-infected p24 antigen-positive persons who had not received prior antiretroviral therapy were treated for 9–13 weeks with an alternating regimen of 1 week of nevirapine (200 mg/day) and 3 weeks of zidovudine (600 mg/day), Serum p24 antigen levels declined during the first week of nevirapine treatment (median, 59%); however, subsequent courses of nevirapine were characterized by rising p24 antigen levels, while antigen levels remained stable or declined during zidovudine treatment. Serum β2-microglobulin levels and CD4+ cell counts exhibited similar responses. HIV-1 isolates obtained from 2 patients revealed 40- and 1000-fold reductions in nevirapine sensitivity after 8 weeks. These findings demonstrate that alternating treatment with zidovudine and nevirapine does not prolong the effectiveness of nevirapine and does not prevent the development of nevirapine resistance.
- Publication
Journal of Infectious Diseases, 1994, Vol 169, Issue 6, p1346
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/169.6.1346